

together



WHO REPORT ON CANCER

SETTING PRIORITIES,
INVESTING WISELY
AND PROVIDING
CARE FOR ALL

2020



World Health
Organization

WHO report on cancer: setting priorities, investing wisely and providing care for all

ISBN 978-92-4-000129-9 (electronic version)

ISBN 978-92-4-000130-5 (print version)

© **World Health Organization 2020**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO report on cancer: setting priorities, investing wisely and providing care for all. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

WHO REPORT ON CANCER

SETTING PRIORITIES, INVESTING WISELY
AND PROVIDING CARE FOR ALL

2020

Table of contents

Acronyms and abbreviations	5
Acknowledgements	6
Executive summary	13
Introduction	17
SECTION I	
Making the Case	22
Chapter 01.	
Global burden of cancer: current and future	23
1.1 Understanding the global burden of cancer	25
1.2 Social and economic inequalities in cancer	32
Chapter 02.	
Positioning cancer as a public health priority	37
2.1 Global commitments to cancer control	39
2.2 Meeting global commitments in the national context	41
2.3 Using a legal framework	46
2.4 Why act now? Understanding the business case	48
SECTION II	
What works in cancer control: Translating evidence into policies and programmes	55
Chapter 03.	
Primary prevention of cancer	57
3.1 Background	59
3.2 Current landscape of cancer prevention	60
3.3 Effective cancer prevention interventions	62
3.4 Integrated approach to cancer primary prevention	65
3.5 Emerging science and programmes	69
Chapter 04.	
Early diagnosis and screening for cancer	71
4.1 Background	73
4.2 Current landscape	78
4.3 Effective interventions for early diagnosis	81
4.4 Effective interventions for screening	82
4.5 Effective strategies for access to high-quality pathology and diagnostic imaging	84
4.6 Integrated approach to early diagnosis and screening	84
4.7 Emerging science and programmes	85

Table of contents

Chapter 05.	
Cancer management.	87
5.1 Background	89
5.2 Current landscape of cancer management services	90
5.3 Setting priorities in cancer treatment	91
5.4 Supportive, survivorship and palliative care	94
5.5 Effective interventions for ensuring equitable access to high-quality care	97
5.6 Coordinated cancer management	102
5.7 Emerging science and programmes	102
SECTION III	
Putting it all together: decision-making and implementation	105
Chapter 06.	
Planning cancer control programmes	107
6.1 Approach to planning and programmes.	109
6.2 Cancer Intelligence and information systems	110
6.3 Strengthening stewardship and leadership in cancer control	114
6.4 Value and priority-setting.	117
6.5 Stepwise priorities in cancer control.	121
Chapter 06.	
Financing cancer control: challenges and strategies.	125
7.1 Background of cancer financing.	127
7.2 Financing cancer services within progressive universal health coverage	127
7.3 Current sources of funding for cancer control	128
7.4 Spending on cancer control: effectiveness, cost-effectiveness, affordability and feasibility	130
Chapter 08.	
Effective implementation: improving capacity and capability	135
8.1 Delivering comprehensive cancer control: background	137
8.2 Preparedness for implementing activities	138
8.3 Scaling-up cancer control	144
8.4 Monitoring and evaluation	145
8.5 Enablers of successful cancer control	146
Conclusions and recommendations	150
Annex 1. WHO tools and resources	152
Annex 2. Glossary and key terms	154
Annex 3. Country Profiles	158

Acronyms and abbreviations

EDL	Essential Diagnostics List
EML	Essential Medicines List
ENDS	electronic nicotine delivery system
ESMO	European Society for Medical Oncology
GDP	gross domestic product
HDI	human development index
HIC	high-income countries
HPV	human papillomavirus
HTA	health technology assessment
IARC	International Agency for Research on Cancer
imPACT	integrated mission of PACT (Programme of Action for Cancer Therapy)
LIC	low-income countries
LMIC	low- and middle-income countries
NCCP	national cancer control programme
NCD	noncommunicable disease
PAF	population attributable fraction
QA	quality assurance
SDG	Sustainable Development Goals
TRIPS	Trade-related Aspects of Intellectual Property Rights
UHC	universal health coverage
WHO FCTC	WHO Framework Convention on Tobacco Control

Acknowledgements

The report was produced by the Department of Noncommunicable Diseases of the World Health Organization (WHO), Geneva, Switzerland under the leadership of Ren Minghui, Assistant Director-General, Universal Health Coverage/Communicable and Noncommunicable Diseases. Etienne Krug, Director, provided key strategic direction.

Executive WHO editors and writers: André Ilbawi, Cherian Varghese.

Executive WHO team: Melanie Bertram, Elena Fidarova, Ariunzul Ganbaatar and Dario Trapani.

We would like to thank the external Editorial Committee for their vision, commitment and guidance: Samar Alhomoud, Manami Inoue, Sharon Kapambwe, Raul Murillo, Rajeev Sadanandan and Richard Sullivan.

Thanks are due to Josep Maria Borrás Andrés for overall technical writing, research support and inputs. We would like to also acknowledge with appreciation Hellen Gellbrand and Cindy Gauvreau, who performed technical review and editing. Primary coordination and project management were performed by Ariunzul Ganbaatar.

WHO Headquarters consultants or volunteers who provided valuable inputs to this Report include: Rei Haruyama, Scott Howard, Catherine Lam and Shilpa Murthy. Statistical analysis and review were provided by Melanie Cowan, Diana Estevez Fernandez and Jessica Ho.

This report benefited from the dedication, support and expertise of a number of WHO staff and external collaborators.

The Headquarters Department of Noncommunicable diseases gratefully acknowledges the contributions from the following individuals at WHO Office:

WHO Regional Offices who provided strategic guidance and direction: Prebo Barango, Marilys Corbex, Gampo Dorji, Warrick Kim, Silvana Luciani, Nasim Pourghazian, Hai-Rim Shin and Slim Slama. WHO Country Offices: Nisreen Abdel Latif, Abdulwahab Al-Nehmi and Elena Vuolo

WHO Headquarters: Shannon Barkley, Douglas Bettcher, Paul Bloem, Allison Colbert, Alison Commar, Gwenael Dhaene, Hebe Gouda, Ivan Ivanov, Benn McGrady, Maria Perez, Vladimir Poznyak, Vinayak Prasad, Dag Rekve, Kiu Siang Tay, Tami Toroyan, Emilie Van Deventer. Sophie Schmitt, Sheila Nakpil and Joel Tarel provided appreciated administrative support.

We would like to express our special thanks to contributors from the International Agency for Research on Cancer (IARC) and International Atomic Energy Agency (IAEA) who provided expert input, data and support.

From IARC, coordination and support were provided by Nicolas Gaudin and Partha Basu under the leadership of Elisabete Widerpass, Director. Valuable data and statistical analyses were performed by Freddie Bray, Filip Meheus, Isabelle Soerjomataram and Eva Steliarova-Foucher.

Valuable support was provided by the International Atomic Energy Agency (IAEA). We would like to acknowledge appreciated contributions by Kirsten Hopkins, Francesco Giammarile, Diana Paez and Eduardo Zubizarreta under the leadership of May Abdel Wahab, Director, Division of Human Health as well as additional inputs by Lisa Stevens, Director, Division of Programme of Action for Cancer Therapy (PACT) Cooperation. Valuable data on country capacity were kindly shared by the Division of Human Health from the DIRAC and IMAGINE databases (Annex 3).

We would like to sincerely thank the many authors, reviewers and other contributors who made this publication possible. The following individuals provided external authorship to specific chapters:

Executive summary: Hellen Gelbrand

Chapter 1: Freddie Bray, Isabelle Soerjomataram.

Chapter 2: Jonathan Liberman with support from Monika Arora, Fatia Kiyange, Miriam Schneidman, Hans Storm.

Chapter 2 (investment case): Melanie Bertram with support from Filip Meheus and Cindy Gauvreau.

Chapter 3: Carolina Wiesner with support from Raul Murillo

Chapter 4: Rengaswamy Sankaranarayanan with support from Silvina Arrossi, Lynette Denny, Ishu Kataria, Groesbeck Parham,

Mohamed Zaghloul

Chapter 5: Josep Maria Borrás Andres, Bishal Gyawali, Eric Krakauer, Dario Trapani

Chapter 6: Tit Albrecht and Jose Martin Moreno with support from Terry Sullivan

Chapter 7: Filip Meheus, Cindy Gauvreau, Hellen Gelband

Chapter 8: Ben Anderson, Catherine Duggan

Country profiles (available online): Dulguun Tugsbayar with support from Ariunzul Ganbaatar and Shilpa Murthy.

Case studies: Jeff Gershenwald, Christine Giles, Catherine Lam, Carlos Rodriguez-Galindo, Lisa Stevens

WHO wishes to thank the following external contributors and reviewers whose expertise made this report possible: Melissa Adde, Anssi Auvénin, Afsan Bhadelia, Gracemarie Bricalli, Fatima Cardoso, Paolo Casali, Ann Chao, Fortunato Ciardiello, Sally Cowal, Piotr Czauderna, Els Dams, Elisabeth de Vries, Maria die Trill, Jean-Yves Douillard, Kalina Duncan, Kenneth Fleming, Lewis Foxhall, Marina Garassino, Jeffrey Gershenwald, Christine Giles, Rosa Giuliani, Bishal Gyawali, Melissa Henry, Cristian Herrera, Ophira Ginsburg, Chris Jackson, Xiaoxiao Jiang, Sonali Johnson, Ravindran Kanesvaran, Emily Kobayashi, Ian Magrath, Tomohiro Matsuda, Keith McGregor, Dan Milner, Tomio Nakayama, Rachel Nugent, Solange Peters, Srinath Reddy, Carlos Rodriguez-Galindo, Felipe Roitberg, Piotr Rutkowski, Suleeporn Sangrajrang, Diana Sarfati, Gretchen Stevens, Lisa Stevens, Josep Taberner, Julie Torode, Guillermo Tortolero-Luna, Ted Trimble, Jane Turner, Vivien Tsu and Malvika Vyas.

Penceo is a Digital Communications Agency offering a 360° approach to marketing, covering Content, Strategy, Design, Social Media, Video and more - www.penceo.com

Design and Layout by Penceo.

This publication was produced with the financial support from the Government of Japan and United States of America (United States National Cancer Institute, grant number 5 U01 AI108543-04) and from the European Society for Medical Oncology, New Sunshine Charity Foundation and St Jude Children's Research Hospital. These partners are thanked for their valuable contributions.



The cancer burden is significant and increasing.

01.

We must act now.

02.



By investing wisely and equitably, cancer

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24816

